Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-Surgical Tirzepatide-Assisted Weight Loss in Prostate Cancer
NCT06759701Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tirzepatide in obesity, Overweight and type 2 diabetes mellitus (T2DM), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and Adverse Events and Study Feasibility up to 2 years. Started Jul 2025; status: recruiting.
02
Drugs
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06759701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06759701.